GenDerm v. Stiefel Labs
This article was originally published in The Tan Sheet
Executive Summary
Patent infringement complaint filed Oct. 14 seeks to bar Stiefel Labs from infringing GenDerm's capsaicin composition patent for Zostrix and Zostrix HP OTC topical analgesic creams. Filed in U.S. District Court for the Southern District of Florida, the complaint claims that Stiefel has infringed the patent by making, using and/or selling topical creams containing the capsaicin compositions. The complaint also seeks treble damages, including lost or reduced profits and attorney's fees. Stiefel subsidiary Glades Pharmaceutical plans to introduce its topical capsaicin cream into national distribution this month. GenDerm also has a suit pending against Ferndale Labs for infringement of two of its capsaicin patents and for trade dress infringement. Zostrix and Zostrix HP have combined annual sales of approximately $20 mil
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning